AU1091200A - Method of treating prostate cancer with an adenovirus vector - Google Patents
Method of treating prostate cancer with an adenovirus vectorInfo
- Publication number
- AU1091200A AU1091200A AU10912/00A AU1091200A AU1091200A AU 1091200 A AU1091200 A AU 1091200A AU 10912/00 A AU10912/00 A AU 10912/00A AU 1091200 A AU1091200 A AU 1091200A AU 1091200 A AU1091200 A AU 1091200A
- Authority
- AU
- Australia
- Prior art keywords
- prostate cancer
- adenovirus vector
- treating prostate
- treating
- adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 241000701161 unidentified adenovirus Species 0.000 title 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16573098A | 1998-10-02 | 1998-10-02 | |
| US09165730 | 1998-10-02 | ||
| PCT/US1999/020907 WO2000020038A1 (en) | 1998-10-02 | 1999-10-01 | Method of treating prostate cancer with an adenovirus vector |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1091200A true AU1091200A (en) | 2000-04-26 |
Family
ID=22600207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU10912/00A Abandoned AU1091200A (en) | 1998-10-02 | 1999-10-01 | Method of treating prostate cancer with an adenovirus vector |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU1091200A (en) |
| WO (1) | WO2000020038A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101261869B1 (en) | 2006-03-28 | 2013-05-07 | 동아쏘시오홀딩스 주식회사 | A gene delivering vector comprising the gene encoding soluble and secretable homotrimer forming recombinant human TRAIL |
-
1999
- 1999-10-01 AU AU10912/00A patent/AU1091200A/en not_active Abandoned
- 1999-10-01 WO PCT/US1999/020907 patent/WO2000020038A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000020038A1 (en) | 2000-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU1527897A (en) | Method for treating the prostate | |
| AU6949498A (en) | Method for assessing prostate cancer | |
| AU1939200A (en) | Electrochemical treatment of malignant tumors | |
| AU6688598A (en) | Method for diagnosing and staging prostate cancer | |
| HUP0000261A3 (en) | Means for treating prostate hypertrophy and prostate cancer | |
| AU6136999A (en) | Method and system for improved detection of prostate cancer | |
| EP1176964B8 (en) | Uses of et743 for treating cancer | |
| HUP0104857A3 (en) | New cancer treatments | |
| AU4823599A (en) | Prostate cancer-associated genes | |
| AU6249098A (en) | Method of treating cancer using alkylglycerols in conjunction with chemotherapy | |
| AU2238499A (en) | Androgen-metabolic gene mutations and prostate cancer risk | |
| AU9689398A (en) | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer | |
| AU9018598A (en) | Prognostic compositions for prostate cancer and methods of use thereof | |
| AU2506499A (en) | Cea/nca-based differentiation cancer therapy | |
| AU1091200A (en) | Method of treating prostate cancer with an adenovirus vector | |
| AU2342299A (en) | Compositions and methods for detecting and treating breast cancer | |
| AU6387499A (en) | Method of treating prostate cancer with an adenovirus expression vector encodinga prodrug enzyme | |
| AU5369498A (en) | Compounds and methods for treating cancer | |
| AU7936898A (en) | Vectors for treating cancer | |
| AU5316099A (en) | Prostate cancer assays and related methods | |
| AU4417996A (en) | Treatment of prostate cancer | |
| AU7130696A (en) | Combination of beta-interferon for the treatment of prostate cancer | |
| AU5097099A (en) | Methods and compositions for cancer treatment | |
| AUPO851597A0 (en) | Treatment of prostate cancer | |
| AU1669600A (en) | New cancer treatments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |